Nimorazole companion diagnostic - Azanta

Drug Profile

Nimorazole companion diagnostic - Azanta

Latest Information Update: 19 Mar 2015

Price : $50

At a glance

  • Originator University of Aarhus
  • Developer Azanta; European Organisation for Research and Treatment of Cancer; The Christie NHS Foundation Trust; University of Aarhus
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer

Most Recent Events

  • 29 Sep 2014 Azanta acquires rights to companion diagnostic of nimorazole from the University of Aarhus
  • 01 May 2014 Phase-III clinical trials in Head and neck cancer (First-line therapy, Late-stage disease) in United Kingdom (unspecified route) (NCT01880359)
  • 01 May 2014 Phase-III clinical trials in Head and neck cancer (Combination therapy, First-line therapy, Late-stage disease) in Belgium and France (unspecified route) (NCT01880359)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top